Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: Designing, synthesis and biological evaluation

Future Medicinal Chemistry

Volumn 9, Issue 11, 2017, Pages 1193-1211

  Kaur, Maninder ^a   Singh, Manjinder ^a   Silakari, Om ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

autoimmune disorders; B cell signaling; Janus kinase 3 (JAK3); molecular dynamics; oxindole; spleen tyrosine kinase (SYK)

Indexed keywords

3 (FURAN 2YL METHYLENE) N METHYL 2 OXOINDOLINE 5 SULFONAMIDE; 3 BENZYLIDENE N METHYL 2 OXOINDOLINE 5 SULFONAMIDE; 3(4 HYDROXYBENZYLIDENE) N METHYL 2 OXOINDOLINE 5 SULFONAMIDE; 3[(1 H INDOL 3 YL) METHYLENE] N METHYL 2 OXOINDOLINE 5 SULFONAMIDE; JANUS KINASE 3 INHIBITOR; N METHYL 2 OXO 3[(PYRIDIN 2YL) METHYLENE]INDOLINE 5 SULFONAMIDE; OXINDOLE; PROTEIN KINASE SYK INHIBITOR; UNCLASSIFIED DRUG; 2-OXINDOLE; ANTIRHEUMATIC AGENT; INDOLE DERIVATIVE; JANUS KINASE 3; PROTEIN KINASE SYK;

ARTICLE; DEFORMITY; DRUG DESIGN; DRUG SYNTHESIS; ERYTHEMA; IC50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOKINETICS; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RHEUMATOID ARTHRITIS; SWELLING; VALIDATION STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; EXPERIMENTAL ARTHRITIS; FEMALE; MALE; MOLECULAR MODEL; STEREOISOMERISM; SYNTHESIS; WISTAR RAT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; DRUG DESIGN; FEMALE; INDOLES; JANUS KINASE 3; MALE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS, WISTAR; STEREOISOMERISM; SYK KINASE;

EID: 85025655646     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2017-0037     Document Type: Article

References (58)

1. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365, 1612-1623 (2011
2. Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin. Investig. Drugs 21, 921-947 (2012
3. Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal. 5, 107-115 (2009
4. Hernández-Flórez D, Valor L. Protein-kinase inhibitors: a new treatment pathway for autoimmune and inflammatory diseases? Reumatol. Clin. 12, 91-99 (2016
5. Myers MR, He W, Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune. Curr. Pharm. Des. 3, 473-502 (1997
6. de Jonge MJ, Verweij J. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? J. Eur. J. Cancer 42, 1351-1356 (2006
7. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422-432 (2008
8. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373 (2007
9. Kontzias A, Laurence A, Gadina M, O?Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 4, 1-8 (2012
10. Kaur M, Singh M, Silakari O. Inhibitors of switch kinase ?spleen tyrosine kinase? in inflammation and immunemediated disorders: a review. Eur. J. Med. Chem. 67, 434-446 (2013
11. Wong BR, Grossbard EB, Payan DH, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13, 743-762 (2004
12. Kyttaris VC, Tsokos GC. Syk kinase as a treatment target for therapy in autoimmune diseases. Clin. Immunol. 124, 235-247 (2007
13. Kontzias A, Kotlyar A, Laurence A, Changelian P, O?Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12, 464-470 (2012
14. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs. 10, 491-504 (2009
15. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des. Devel. Ther. 6, 245-250 (2012
16. Mullard A. 2012 FDA drug approvals. Nat. Rev. Drug Discov. 12, 87-90 (2013
17. Blunt MD, Parnell J, Larrayoz M, et al. 57th Annual Meeting & Exposition. FL, USA (Dec 5-8, 2015
18. Rudrangi SR, Bontha VK, Manda VR, Bethi S. Oxindoles and their pharmaceutical significance-an overview. Asian J. Res. Chem. 4, 335-338 (2011
19. Lai JY, Cox PJ, Patel R, et al. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg. Med. Chem. Lett. 13, 3111-3114 (2003
20. Adams C, Aldous DJ, Amendola S, et al. Mapping the kinase domain of Janus Kinase 3. Bioorg. Med. Chem. Lett. 13, 3105-3110 (2003
21. Maestro, version 9.3, User Manual, Schrödinger, LLC, New York, NY (2012
22. Ligprep, version 2.5, User Manual, Schrödinger, LLC, New York, NY (2012
23. PHASE, version 3.4, Schrödinger, LLC, New York, NY (2012
24. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647-671 (2006
25. Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design -a review. Curr. Top. Med. Chem. 10, 95-115 (2010
26. Kaur M, Kumari A, Bahia MS, Silakari O. Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol. J. Mol. Graph. Model. 39, 165-175 (2013
27. Weaver S, Gleeson MP. The importance of the domain of applicability in QSAR modeling. J. Mol. Graph. Model. 26, 1315-1326 (2008
28. Mouchlis VD, Melagraki G, Mavromoustakos T, Kollias G, Afantitis A. Molecular modeling on pyrimidine-urea inhibitors of TNF-α production: an integrated approach using a combination of molecular docking, classification techniques, and 3D-QSAR CoMSIA. J. Chem. Inf. Model. 52, 711-723 (2012
29. Cramer RD, Bunce JD, Patterson DE, Frank IE. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 7(1), 18-25 (1988
30. Golbraikh A, Tropsha A. Beware of q2 J. Mol. Graph. Model. 20, 269-276 (2002
31. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221-234 (2013
32. Research Collaboratory for Structural Bioinformatics. Protein data bank. www.rcsb.org/pdb/home/home.do
33. Lucas MC, Goldstein DM, Hermann JC, et al. Rational design of highly selective spleen tyrosine kinase inhibitors. J. Med. Chem. 55, 10414-10423 (2012
34. Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832 (2004
35. Thoma G, Blanz J, Bühlmayer P, et al. Syk inhibitors with high potency in presence of blood. Bioorg. Med. Chem. Lett. 24, 2278-2282 (2014
36. Kozlov G, Vinaik R, Gehring K. Triosephosphate isomerase is a common crystallization contaminant of soluble His-tagged proteins produced in Escherichia coli. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 69, 499-502 (2013
37. Forns P, Esteve C, Taboada L, et al. Pyrazine-based Syk kinase inhibitors. Bioorg. Med. Chem. Lett. 22, 2784-2788 (2012
38. McLean LR, Zhang Y, Zaidi N, et al. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. Bioorg. Med. Chem. Lett. 22, 3296-3300 (2012
39. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J. Med. Chem. 57, 3856-3873 (2014
40. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 400, 413-433 (2010
41. Soth M, Hermann JC, Yee C, et al. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. J. Med. Chem. 56, 345-356 (2013
42. Thoma G, Nuninger F, Falchetto R, et al. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J. Med. Chem. 54, 284-288 (2011
43. Godemann R, Madden J, Krämer J, et al. Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 48, 10743-10751 (2009
44. Ellermann M, Jakob-Roetne R, Lerner C, et al. Molecular recognition at the active site of catechol-o-methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor. Angew. Chem. Int. Ed. Engl. 48, 9092-9096 (2009
45. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002 (2005
46. Clark AJ, Tiwary P, Borrelli K, et al. Prediction of proteinligand binding poses via a combination of induced fit docking and metadynamics simulations. J. Chem. Theory Comput. 12, 2990-2998 (2016
47. Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem. Biol. Drug Des. 67, 83-84 (2006
48. QikProp, version 3.5 Schrodinger, LLC, New York, NY (2012
49. Prime, version 3.1. Schrödinger, LLC, New York, NY (2012
50. Sun L, Tran N, Liang C, et al. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 42, 5120-5130 (1999
51. Wahl A, Bagard P. Sur un nouvel isomère de l?indigotine; par MM. Bull. Soc. Chim. 5, 1033-1039 (1909
52. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595 (1987
53. Rodems SM, Hamman BD, Lin C, et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev. Technol. 1, 9-19 (2002
54. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999
55. Desmond Molecular Dynamics System, version 2.2. D. E. Shaw Research, New York, NY, USA (2009
56. Badger AM, Griswold DE, Kapadia R, et al. Diseasemodifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43, 175 (2000
57. Bendele A. Animal models of rheumatoid arthritis. J. Musculoskelet. Neuronal Interact. 1, 377-385 (2001
58. Coffey G, Betz A, DeGuzman F, et al. The novel kinase inhibitor PRT062070 (cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J. Pharm. Exp. Ther. 351, 538-548 (2014